拉米夫定和α-干扰素序贯治疗e抗原阴性乙肝患者及其对
拉米夫定耐药突变的抑制
宫航宇;綦盛麟;石铭;宋连平
【期刊名称】《中国医药导报》 【年(卷),期】2011(008)014
【摘要】Objective: To evaluate the effect of lamivudine and interferon sequential treatment of patients with chronic hepatitis be antigen negatie.Methods: 162 cases of e antigen negatie patients with chronic hepatitis b treatment were studied.98 cases were treated by lamivudine alone 100 mg, daily.Continuous treatment for 48 weeks (group B).64 patients were first used alone lamivudine 100 mg every day, continuous treatment for 20 weeks, then combination, increase of alpha interferon 5 million units, 3 times a week, continuous treatment after 4 weeks, instead of alpha interferon used alone (5 million units, 3 times a week), continuous treatment 24 weeks (group A).All patients continue treatment 24 weeks.Results: After 48 weeks of treatment, ALT complex and often HBV-DNA reduced to less than 1 000 copies/ml in the percentage of patients in both groups were not significantly different.Lamivudine treatment group ALT alone complex and often HBV-DNA less than 1 000 copies/ml ratio for 55.1％, interferon sequential treatment group two ratio for 59.36％ and 56.25％.And in the treatment of 72 weeks, ALT complex often proportion of group A (53％)
拉米夫定和α-干扰素序贯治疗e抗原阴性乙肝患者及其对拉米夫定耐
